ASPI · ASP Isotopes Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Headline loss non-GAAP | -$30.13M | Three Months Ended June 30, 2026 filing | — |
| Headline loss per share, attributable to ASP Isotopes Inc. shareholders, basic and diluted non-GAAP | -$0.25 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASPI
this stock
ASP Isotopes Inc.
|
$605.57M | -26.2% | +475.5% | — | 17.4% |
|
SHECF
Shin-Etsu Chemical Co., Ltd.
|
$73.14B | +20.5% | — | — | 0.2% |
|
DOW
Dow Inc.
|
$23.71B | +40.7% | -7.0% | — | 4.9% |
|
NPXYY
Nippon Sanso Holdings Corporation/ADR
|
$15.32B | +19.1% | — | — | 0.0% |
|
CE
Celanese Corp
|
$5.16B | +11.1% | -7.1% | — | 7.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASPI | -7.7% | -2.2% | -26.0% | -1.3% | -26.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -5.8% | -5.5% | -37.2% | -3.3% | -38.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.